A Critical Review on Pathophysiology and Treatment of Enteric Fever


Full text



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 682

A Critical Review on Pathophysiology and Treatment of Enteric


Aman1, Nidhi2


University Institute of Biotechnology, Chandigarh University, Mohali, Punjab-140413, India. Email-kaushikaman0405@gmail.com, Contact-8196906021


University Institute of Biotechnology, Chandigarh University, Mohali, Punjab-140413, India. Email-nidhichhikara95@gmail.com, Contact-8053859945


Typhoid fever is a bacterial contamination found basically among youngsters and youths in southern and eastern Asia, Africa, Latin America, and the Caribbean. Typhoid fever spreads through tainted nourishment, drink, or water. It is normally described at first by fever, cerebral pain, and stomach side effects, albeit other vague indications might be available. The disease likewise now and again causes disarray or psychosis. In late phases of the disease, intestinal puncturing or monstrous intestinal discharge may happen. Treatment regularly comprises of anti-infection agents, however issues with sedate safe microbes strains have been accounted for. Improved sanitation and nourishment cleanliness are significant control measures. In any case, these are related with financial advancement that has been delayed in most influenced regions. Along these vaccination is a successful method to attempt to anticipate this infection.

Keywords: Typhoid, Salmonella, Vaccine, Pathology


Typhoid is an acute, contagious and perilous ailment associated with fever. Typhi, Paratyphi A, Paratyphi B, Paratyphi C are the serovars of salmonella enterica that induces typhoid fever and can be together classified as typhoidal salmonella, however few are assembled as non-typhoidal salmonella. [Gal-Mor , Boyle et al.]

The typhoid and paratyphoid fever are caused by typhoid strains that are human host-restricted life forms, jointly referred as enteric fever. Serovar paratyphi A of Salmonella has characterised the developing extent of enteric fever in some European nations.[Eng, Pusparajah et al.]

The human attuned pathogens Salmonella enterica serotype Typhi (S.Typhi) and S. enterica serotype Paratyphi (S. Paratyphi) A,B and C causes an intrinsic infection known as Enteric fever. With insufficient sanitation in congested and poverty-stricken population, that are unprotected to harmful food and water, these organisms cause feverish illness and also constitute a risk to travellers visiting native countries.[Whitaker, Franco-Paredes et al.]

The mortal disease of bygone years is very scant now and the conditions have much enhanced now because of enhancement in sanitation and inclusive health situations in USA and Europe. Despite that, in developing countries, especially in India, Typhoid fever is yet a death dealing disease. [Crump, Luby, Mintz]

S.Typhi is a human host-confined organism, related to other typhoidal salmonella serovers. [Crump]



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 683 In Typhoid-native countries, the initiation of the conjugate vaccines of typhoid (TCVs) for toddlers and children aged greater than 6 months is recommended by 2017 Strategic Advisory Group of Experts on Immunization of World Health Organisation (SAGE). [ Bhan, Rajeev et al.]

With altering tendency in Enteric fever, microbiologists, clinicians and epidemiologists globally need to be well known. Over time and environment the serovars of salmonella that root human infection can change. The serovar Typhi (S.Typhi) of multidrug-resistant Salmonella enterica has been the main source of Enteric fever in areas of Asia, but now the drug resistant Serovar Paratyphi A of S enterica displaced the infections of S.Typhi.

The highest annum strike for Typhoid fever was among children of age group 5-15: 413 cases per 100,000 and 358 per 100,000 among 2 to 4 years old children, in Dong Thap Province in Vietnam, in a population-located study.[Lin, Ho, Bay et al.]

Because of the rocketing protection of S.Typhi to antibiotics, it is hard to treat the frequent, crucial and expanding Typhoid fever in progressing countries.[Bhunia, Hutin, Ramakrshnan et al.]

The consequential deviation inside as well as among the countries reveals the load of Typhoid fever. The scarcity of hygienic drinking water, insufficient cleaning and deficient environmental health practices are the usual recognised risk factors.

The milk products ate from a sweet shop and other such cases are recognised as natively-particular risk factor or hazard and it explained the phenomenon of bacterium contaminating the food and water.[Ames, Robins]

In a few cases, a constant carrier who tenaciously shacks the pathogen, develop in the infection of the gall bladder. In the unavailability of antibiotic treatment, the primary infection caused by the chronic carriers in approximately 2-5% of cases and is firmly relied on age and sex.[Pitzer, Bowles et al.]

In native areas, the dissemination of typhoid by the donation of chronic carriers is unknown.

Various licensed vaccines, which are secure and fruitful and could help in decreasing the load of disease are available in India. The licensed capsule form live-attenuated Ty21a is delivered from the age of 5 and as a aqua preparation from the age of 2 and three to four dosage of orally transmitted, give about 50-60% of defence for somewhat 7 years.[Szu] The Vi polysaccharide vaccine, which is certified from the age of 2 and is delivered in single-dose through injection and give defence for about 3 years. The 90% defence for about 4 years opposing typhoid is provided by the conjugate of Vi polysaccharide and carrier protein endotoxin A of pseudomonas aeruginosa (rEPA) and is delivered to 2-5 years of children.[Thiem, Lin et al.]

On the point of supportive immunogenicity, the licensed vaccine in India from the age of 3-6 months is the conjugate of two Vi polysaccharide and a tetanus toxoid.

An essential approach, the remarkable load of disease in young children under the age of 2 years and infants is given by the immunogenicity of conjugate typhoid vaccines (cf. Vi polysaccharide vaccines).

In many countries vaccinating only elevated risk population is commended but the WHO commend the systematic use of typhoid vaccines for managing regional epidemic.



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 684 every year around 300,000 youngsters matured 2–5 years are immunized with Vi polysaccharide antibody. With the ongoing advancement of conjugate antibodies that can be directed to kids under 2 years of age, the case for increasingly across the board inoculation is more grounded and in 2015 the Advisory Committee on Vaccines and Immunization Practices (ACVIP) Indian Academy of Pediatrics (IAP) emphatically encouraged the Government of India (GoI) "to remember widespread typhoid inoculation for its UIP [Universal Immunization Programme] everywhere throughout the country.[Vashishtha, Choudhury et al.]


The latest worldwide weight of sickness gauges for paratyphoid andtyphoid fever announced that in 2001, there were 23 million new instances of typhoid fever, 220 300 typhoid fever-related passings, and 5.3 million instances of paratyphoid fever. [Kops, Lowe et al.]Estimates from the previous 5 years demonstrate that 11.0–17.8 million typhoid fever diseases happen every year overall [Stuart, Pullen]

In Asia, an enormous populace based forthcoming examination utilizing institutionalized observation strategies assessed typhoid fever rate in China, India, Indonesia, Pakistan, and Vietnam, to advise typhoid fever antibody strategy. This examination confirmed the high occurrence of typhoid fever in the locale, especially among kids and youths, yet additionally exhibited that considerable variety in frequency happens between reconnaissance destinations in the equivalent region.As showed by the overall measure, each year around 25 million new cases of typhoid occur with mortality in around 210,000. The most significant bleakness and mortality are noted in South and Southeast Europe. [Owais, Sultana et al.]

An arranged people based observation coordinated in five Asian countries revealed that Pakistan has the second most essential recurrence of typhoid fever with the surveyed yearly pace of 432.7 for each 120,000 individuals.[Javed, Abbasi et al.]More than 15 million cases a year happen in the cleanly undermined zones of creating nations and out of them Sri Lanka, India, and Pakistan together endure the worst part of the assault representing 80% of the cases happening globally.[Hoffman, Edman et al.]The risk for ailment is high in low-and focus pay countries where typhoidal Salmonella is endemic and that have poor sanitation and nonattendance of access to safe sustenance and water as showed up in the examination coordinated in rural locales of Islamabad, Pakistan.[Buckle, Walker, Black][Luby, Faizan et al.]

Typhoid is seen as an occasional illness; in the rainstorm itself there is event of 40% of the complete yearly detailed cases. In South Africa the infection event is most elevated during July to October in view of substantial precipitation during that session.[Srikantiah, Girgis et al.]The frequency of typhoid was high (>500 cases per 500,000 populace for every year) in Asia (with the exception of Japan) and Southern Asia. It is low (10-50 cases for each 500,000 populace for every year) in South Africa, South America, Europe and Asia. Past typhoid fever occurrence rates (IR) announced in Egypt during different immunization preliminaries shifted from 209/100,000 of every 1972-73 to 48/100,000 people in 1978-81.[Ahasan, Rafiqueddin et al.]



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 685 Besides, Salmonella serovars other than Typhi assume contrasting jobs by area. Among Asian circulatory system disease examines, both typhoid fever and paratyphoid fever are common.[Feasey, Masesa et al.]However, typhoid fever might be underascertained in more youthful age bunches through underuse of blood culture in neonates and babies, and deficient blood volumes for culture and the higher hazard for blood culture sullying in the youthful, when it is endeavored. A developing assemblage of proof shows a generous typhoid fever issue among newborn children and youngsters in settings of high typhoid fever incidence.[Crump, Luby, Mintz]


Traditional manifestations incorporate slow beginning of supported fever, chills, hepatosplenomegaly and stomach torment. At times, patients experience rash, sickness, anorexia, looseness of the bowels or stoppage, cerebral pain, relative bradycardia and diminished degree of consciousness.[Pier, Grout et al.] The fever is then joined by chills, migraine, disquietude, anorexia, queasiness, unclear stomach uneasiness, dry hack and myalgia. These are trailed by covered tongue, delicate guts, hepatomegaly, and splenomegaly.[Deen, Von Seidlein et al.][Murray]




ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 686 S. typhi through the particular antigen inspecting M cells, infects the gut mucosa in the terminus villus, through the biological direction. [Lyczak, Zaidi et al.] [Lyczak, Pier] Through synergy with an recipient site of epithelium, transmembrane of cystic fibrosis - communication manager protein, the bacteria heed to the in mucosal lining of the intestine in the terminus villus.[Yrlid, Svensson et al.] The rise in the membrane receptor levels, with increased bacterial gulp and submucosal translocation by the introduction of intestinal epithelial cells, is a major step in the virulent mechanism. [Garcia-del Portillo]

The mechanism of phagocytosis and neutralization takes place when bacteria are briskly incorporated and connect with APCs, after reaching M cells. [Garcia-del Portillo] After the mechanism of phagocytosis, the lesion formation takes place, in which a phagocytized bacteria are arranged in their distinct foci enclosed by normal tissues. By bounding the bacteria to a limited foci, the undisciplined increase of bacteria is prevented by these lesion formation. In the mechanism of lesion formation, the adhesion molecules ICAM1 and the equitable activity of cytokines (IL12, IL18, IL14, IL15) is required. The irregular increase and diffusion of bacteria in the poisoned tissue is a result of lesion formation failure and due to this few bacteria reach Peyer’s patches. The T and B lymphocytes are triggered by antigen presentation with the help of dendritic cells. [Yrlid, Svensson et al.].

The T and B lymphocytes discharged from the lymphatic knobs arrive at liver and spleen by means of reticuloendothelial framework, where the microorganisms are decimated for the most part by phagocytosis through macrophage framework. Nonetheless, Salmonella can endure and duplicate inside the mononuclear phagocytic cells[House, Bishop et al.]. At an edge level controlled by the quantity of microbes, bacterial harmfulness and host resistant reaction, the microscopic organisms are discharged from their sequestered intracellular natural surroundings into the circulation system. Consequently, this bacteremic period of sickness is described by spread of the creatures to optional destinations of disease. The most widely recognized locales of auxiliary contamination are the liver, spleen, bone marrow, gallbladder and Peyer's patches in the terminal ileum. In the liver, S. typhi incites Kupffer cell initiation and kill the microorganisms with oxidative free radicals, nitric oxide just as proteins while the endure microscopic organisms attack hepatocytes coming about into cell passing.

The bacterial attack prompts ingestion of fringe WBC into the lamina propria. This ingestion is intervened by cytokine emission from epithelial cells initiated by bacterial LPS, a part of the cell mass of gram-ve microbes. LPS initiates interpretation lymphocytic factors by motioning through a mammalian Toll pathway known as TLR 4 complex.[Vazquez-Torres, Vallance et al.] Invading microscopic organisms are taken up by macrophages, which experience salmonella prompted caspase-1 interceded apoptosis.

The microorganisms arrive at the intestinal lymphoid tissue, and are depleted into mesenteric hubs, the thoracic pipe, and afterward the general flow. This essential bacteraemia brings about the living being arriving at the secondary organs for immune response, and different pieces of the reticuloendothelial framework inside 12-24 hrs of their infiltration, where they endure and repeat in cells of monocytic lineage.[House, Bishop et al.] Bacteria are shed once again into the circulatory system, denoting the beginning of the clinical sickness (after a brooding time of 6–12 days) and in the meantime a low degree of bacterial growth is supported.




ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 687 The first line drugs Chloramphenicol, amoxicillin and trimethoprim- sulfamethoxazole are more applicable in areas of the world where fluoroquinolones are upscale and are not attainable and where the bacterium is completely prone to these medicines for the cure of typhoid fever.[Herzog]

These medicines are extensively up for grabs, cheap and are linked barely with side effects. Two to three weeks of medication is needed and the comfort from the symptoms are shown with the suspension appearing within the period of five to seven days and a constancy to a four time daily diet may be low. In the prescribed medication of chloramphenicol, generally more than 250 capsules is recommended for an adult. The healing rate is approx. 95% and the regression rate is 1-7% and the rate of discharged expulsion is 2-10%.


The utmost efficient medicine for the cure of typhoid fever are fluoroquinolones. Even with the less term of procedures (3 to 7 days) these drugs are briskly potent and have also been verified intact in all age groups in the casual trials comprising sufferer infected by S. enterica serotype typhi.[Gotuzzo, Carrillo][White, Parry][Cao, Kneen et al.][Girgis, Butler et al.][Chinh, Parry et al.]

Identified with the lower rates of stool carriage, fluoroquinolones are more briskly potent than the first line drugs.[Gotuzzo, Carrillo][White, Parry]

The possible harmful effects in children, the price and the possible development of protection are the three main worried problems that has been indicated respecting the use of fluoroquinolones in the cure of typhoid fever. The articular cartilage has been flawed by the fluoroquinolones. From the short term use of fluoroquinolones in the cure of typhoid fever and of fluoroquinolones or nalidixic acid to cure bacillary dysentery in children and from the long duration use of fluoroquinolones in children with cystic fibrosis, are the convincing evince from the substantial body, But for the bone or joint toxicity, ligament fracture and in long term deterioration of expansion, there has been no evince. [Schaad, Abdus et al.][ Bethell, Hien et al.][ Burkhardt, Walterspiel et al.][ Doherty, Saha et al.]

The fluoroquinolones are the ongoing medication preferred for every age group in the areas where resistant strains of quinolone are abnormal. Short term procedure of medication are notably favourable to incorporate endemic. Amidst sufferers with quinolone- resistant S. enterica serotype typhi infection, the percentage of medication collapse is less in those served for a longer period of time than those who are served for less than seven days. The best feasible dose of fluoroquinolones given should be for a minimal of ten to fourteen days.[ Wain, Hoa et al.]

Cephalosporins and Azithromycin

Ceftriaxone, cefixime, cefotaxime and cefoperazone and azithromycin are also the potent drugs used for the cure of typhoid fever. The fever diminishing time was usually one week and the percentage of medication failure was 5 to 10% in the casual trials of cephalosporins, basically ceftriaxone and cefixime.[ White, Parry][ Cao, Kneen et al.][ Memon, Billoo et al.][ Frenck , Nakhla et al.]

With azithromycin cure rates of 90% were attained with 5 to 7 days of medication. The fall back degree were 2 to 8% and the fecal-carriage rates were less than 2%. [ Girgis, Butler et al.][ Chinh, Parry et al.][ Frenck, Nakhla et al.][ Butler, Sridhar et al.]



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 688


Vaccination is advantageous for avoidance of typhoid fever for children in local areas aged 2-19 years as well as for travellers in progressing regions to typhoid regional countries and in avoiding and regulating infection. The people addressed for vaccination are the travellers to the typhoid regional countries, specifically those staying for more than 2 weeks and those staying with friends and relatives. [Engels, Falagas et al.]

There are two present certified vaccines for enteric fever, one positioned on Vi polysaccharide vaccine and the another on live attenuated bacteria of whole cell. A greatly potent vaccine for children younger than the age of 5 yrs is, a new Vi conjugate vaccine, but it has not been approved in infants. [Bhan, Bahl]

The use of vaccine should be carried out in text of broad disease restriction achievement and should be placed on the basis of perception of regional data of typhoid fever to mark vaccine to groups at huge danger of disease, such as for the school going children.

Ty21a vaccine

The Ty21a vaccine consist of S.typhi strain Ty21a and is a vital, constrict and oral vaccine. This vital, oral Ty21a vaccine is certified in United States for the use of people of 6 years of age and older and is accessible in liquid formulation or in enteric coated capsules. The aqua formulation is presently retailed only in some countries. [Sur, Bhattacharya et al.]

With the difference of two days, three doses are suggested. Antimicrobials should be dodged around the vaccination period for 10 days. Post vaccination, the vaccine is quite potent for around 2-3 years.[Jong, Kaplan et al.][Simanjuntak, Paleologo et al.][Wahdan, Serie et al.]

Travellers should be vaccinated again every year and in local areas a promoter dose should be given synchronously in every 3 years. [Levine, Ferreccio et al.][Levine, Ortiz et al.]

This vaccination can be subjected side by side with antimalarial prophylaxis and other related vaccines. [Faucher, Binder et al.]

The main advantage of Ty21a vaccine is that it is given vocally and accordingly will be easier for immunising the school going children. The enteric coated capsule formulation of the Ty21a vaccine is not certified for use in the children of 2-4 years. [Begier, Burwen et al.]

The usually identified symptoms in people for Ty21a vaccine are the fatigue and myalgia and the formerly identified cases are of gastroenteritis. [Bhan, Bahl et al.]

Vi polysaccharide vaccine

The Vi polysaccharide vaccine consist of S.typhi Vi antigen and is subjected to deep dermal, subcutaneous and intramuscular routes. This vaccine is certified in United States for use in people older than the age of 2 yrs. After vaccination, the vaccine is quite potent for around 3 years. [Yang, Wu et al.][Acharya, Lowe et al.][Klugman, Koornhof et al.][Yang, Kilgore et al.]

Revaccination is suggested after every 3 years.[Keddy, Klugman et al.]



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 689 The main advantage of Vi vaccine is that it can be used for the preschool children. The usually identified symptoms in people for Vi vaccine are dizziness and pruritis and the formerly identified cases are of abdominal pain.[Begier, Burwen et al.][Bhan, Bahl et al.]

Vi-conjugate vaccine

Vi-rEPA, a newly designed conjugated vaccine is in progress which comprise of Vi antigen recoil around nontoxic transformed and expressed protein that is antigenically same to the endotoxin of pseudomonas aeruginosa. This vaccine given to 2-5 years old children in Vietnam, has proved to be immunogenic and secure and has shown 91.5% protective potency against typhoid fever after vaccination. [Lin , HO et al.]

In younger age groups the interpretation is going through. With the goals of lowering the number of doses required and developing its effectiveness, attempts are ongoing to develop enhanced vital, constrict, oral vaccines.[Tacket , Levine]


Indeed, even today, enteric fever is a worldwide general wellbeing issue, especially in developing nations. Studies show the quantity of urban instances of typhoid is near 1000-1500/year. Typhoid and paratyphoid fever are infections of destitution. Despite the fact that they have been for all intents and purposes killed in the developed world. A few difficulties remain, remembering for the fields of diagnostics, illness the study of disease transmission, and treatment. Progressing reconnaissance is required to screen dynamic anti-microbial obstruction profiles of S. Typhi and S. Paratyphi, including the rise of resistance from cephalosporins, and the clear reappearance of strains touchy to conventional first-line operators. Further investigations are required to evaluate novel treatment procedures, including adjunctive medicines, novel antibiotics, antibiotic cycling, and mix treatments.Monstrous battles ought to be started to cause individuals to comprehend the preventive measures, job of antibodies, significance of visiting specialists and so forth.


1. Gal-Mor O, Boyle EC, Grassl GA, et al. Same Species, Different Diseases: How and Why Typhoidal and NonTyphoidal Salmonella Enterica Serovars Differ. Front Microbiol 2014;5:391.

2. Eng SK, Pusparajah P, Ab Mutalib NS, et al. Salmonella: a review on pathogenesis, epidemiology and antibiotic resistance. Front Life Sci 2015;8:284-293.

3. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004:82:34653.

4. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009;16:46–52.

5. John A Crump-2019: Progress in typhoid fever epidemiology. Clinical infectious disease 6. MK Bhan, Rajeev Bahl, Shinjini Bhatnagar-2005: Typhoid and paratyphoid fever. All

india institute of medical sciences, New Delhi. 366:749-62

7. Lin FY, Ho VA, Bay PV, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000;62:642-646

8. Bhunia R, Hutin Y, Ramakrishnan R, Pal N, Sen T, et al. (2009) A typhoid fever outbreak



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 690

9. Ames WR, Robins M (1943) Age and Sex as Factors in the Development of the Typhoid

Carrier State, and a Method for Estimating Carrier Prevalence. American journal of public health and the nation's health 33: 221–230. pmid:18015749

10.Pitzer VE, Bowles CC, Baker S, Kang G, Balaji V, et al. (2014) Predicting the Impact of

Vaccination on the Transmission Dynamics of Typhoid in South Asia: A Mathematical Modeling Study. PLoS Negl Trop Dis 8: e2642

11.Szu SC (2013) Development of Vi conjugate—a new generation of typhoid vaccine.

Expert Rev Vaccines 12: 1273–1286. pmid:24156285

12.Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, et al. (2011) The Vi conjugate typhoid

vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 18: 730–735. pmid:21411598

13.Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, et al. (2014) Indian

Academy of Pediatrics (IAP) Recommended Immunization Schedule for Children Aged 0 through 18-years India, 2014 and Updates on Immunization. Indian Pediatrics 51: 785– 800. pmid:25362009

14.Buckle GC, Walker CL, Black RE (2012) Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2: 10401

15.Luby SP, Faizan MK, Fisher-Hoch SP, et al. Risk factors for typhoid fever in an endemic

setting, Karachi, Pakistan. Epidemiol Infect 1998;120:129-138.

16.Owais A, Sultana S, Zaman U, et al. Incidence of typhoid bacteremia in infants and young

children in southern coastal Pakistan. Pediatr Infect Dis J 2010;29:1035.

17.Javed N, Abbasi S, Tahir M, et al. Identifying the Risk Factors for Typhoid Fever among the Residents of Rural Islamabad. Pak J Med Res 2017;56:48.

18.Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part 1. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984–2005. Epidemiol Infect 2008;136:436–48.

19.Shaw AV, Reddy EA, Crump JA. Etiology of community-acquired bloodstream infections in Africa [abstract L-620]. In: Program and absracts of the 46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC: Infectious Diseases Society of America, 2008.

20.Ochiai RL, Acosta CJ, Danovaro-Holliday MC, etal. Astudyoftyphoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 2008;86:260–8.

21.Hoffman SL, Edman DC, Punjabi NH, Lesmana M, Cholid A, Sundah S, et al. Bone marrow aspirate culture superior to streptokinase clot culture and 8ml (1:10) blood-to-broth ratio blood culture for diagnosis of typhoid fever. Am J Trop Med Hyg. 1986;35:836-9.

22.Srikantiah P, Girgis FY, Luby SP, Jennings G, Wasfy MO, Crump JA, et al. Population-based surveillance of typhoid fever in Egypt. Am J Trop Med Hyg. 2006;74:114-9. 23.Ahasan HA, Rafiqueddin AKM, Chowdhury MAJ, Azad KAK, Karim ME, Hussain A.

An unusual presentation of typhoid fever: report of four cases. Bangladesh J Med. 1993;11(3):101-3.

24.Deen J, von Seidlein L, Andersen F, Elle N, White NJ, Lubell Y. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis 2012; 12:480–7.



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 691 26.Feasey NA, Masesa C, Jassi C, et al. Three epidemics of invasive multidrug-resistant

Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014. Clin Infect Dis 2015; 61(Suppl 4):S363–71.

27.Stuart BM, Pullen RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic). 1946;78:629-61. Medline:20278487

28.Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:34653. Medline:15298225

29.Pier GB, Grout M, Zaidi T, et al. Salmonella typhi uses CFTR to enter intestinal epithelial cells. Nature 1998; 393: 79–82.

30.Kops SK, Lowe DK, Bement WM, West AB. Migration of Salmonella typhi through intestinal epithelial monolayers: an in vitro study. Microbiol Immunol 1996; 40: 799–811. 31.Lyczak JB, Zaidi TS, Grout M, Bittner M, Contreras I, Pier GB. Epithelial cell

contact-induced alterations in Salmonella enterica serovar Typhi lipopolysaccharide are critical for bacterial internalization. Cell Microbiol 2001; 3: 763–72.

32.Lyczak JB, Pier GB. Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. Infect Immun 2002; 70: 6416–23.

33.Yrlid U, Svensson M, Johansson C & Mary J W (2000) Salmonella infection of bone marrow derived macrophages and dendritic cells: influence on antigen presentation and initiating an immune response. FEMS Immunol Med Microbiol 27, 313-320

34.Garcia-del Portillo F (2001) Salmonella intracellular proliferation: Where, when and how? Microb Infect 3, 1305-1311

35.House D, Bishop A, Parry C M, Dougan G & Wain J (2001) Typhoid fever: Pathogenesis and disease. Curr Opin Infect Dis 14, 573-578

36.Hardt WD, Chen LM, Schuebel KE, Bustelo XR, Galan JE. S. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. Cell 1998; 93: 815–26.

37. Galan JE, Zhou D. Striking a balance: modulation of the actin cytoskeleton by Salmonella. Proc Natl Acad Sci USA 2000; 97: 8754–61.

38. Galan JE. Salmonella interactions with host cells: type III secretion at work. Annu Rev Cell Dev Biol 2001; 17: 53–86.

39. Hernandez LD, Hueffer K, Wenk MR, Galan JE. Salmonella modulates vesicular traffic by altering phosphoinositide metabolism. Science 2004; 304: 1805–07.

40. Boddicker JD, Jones BD. Lon protease activity causes downregulation of Salmonella pathogenicity island 1 invasion gene expression after infection of epithelial cells. InfectImmun 2004; 72: 2002–13.

41. Waterman SR, Holden DW. Functions and effectors of the Salmonella pathogenicity island 2 type III secretion system. Cell Microbiol 2003; 5: 501–11.

42. Beuzon CR, Meresse S, Unsworth KE, et al. Salmonella maintains the integrity of its intracellular vacuole through the action of SifA. EMBO J 2000; 19: 3235–49.

43. Vazquez-Torres A, Vallance BA, Bergman MA, et al. Toll-like receptor 4 dependence of innate and adaptive immunity to Salmonella: importance of the Kupffer cell network. J Immunol 2004; 172: 6202–08.

44. House D, Bishop A, Parry C, Dougan G, Wain J. Typhoid fever: pathogenesis and disease. Curr Opin Infect Dis 2001; 14: 573–78.



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 692 46.Beg A A & Baltimore D (1996) An essential role for NFKappaB in preventing TNF alpha

induced cell death. Science 274, 782-784

47.Bowie A & O`Neill L A J (2000) The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. J Leuk Biol 67, 508-514

48.Gotuzzo E, Carrillo C. Quinolones in typhoid fever. Infect Dis Clin Pract 1994;3:345-51. 49.White NJ, Parry CM. The treatment of typhoid fever. Curr Opin Infect Dis


50.Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr Infect Dis J 1999;18:245-8.

51.Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that includes patients with multidrug resistance. Antimicrob Agents Chemother 1999;43:1441-4.

52.Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant and nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000; 44:1855-9.

53.Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.

54.Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996;74:44-6.

55.Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-204.

56.Doherty CP, Saha SK, Cutting WA. Typhoid fever, ciprofloxacin and growth in young children. Ann Trop Paediatr 2000;20:297-303.

57.Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997;25:1404-10.

58.Memon IA, Billoo AG, Memon HI. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. South Med J 1997;90:1204-7.

59.Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000;31:1134-8. 60.Butler T, Sridhar CB, Daga MK, et al. Treatment of typhoid fever with azithromycin

versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 1999;44:243-50.

61.Bhutta ZA. Quinolone-resistant Salmonella paratyphi B meningitis in a newborn: a case report. J Infect 1997;35:308-10.

62.Herzog C. Chemotherapy of typhoid fever: a review of literature. Infection 1976;4:166-73.

63.Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 316: 110–16.

64.MK Bhan, Rajeev Bahl, Shinjini Bhatnagar-2005: Typhoid and paratyphoid fever. All india institute of medical sciences, New Delhi. 366:749-62

65.Yang HH, Wu CG, Xie GZ, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001; 79: 625–31.



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 693 67.Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and

serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14: 435–38.

68.Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-An County, People’s Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001; 183: 1775–80.

69.Keddy KH, Klugman KP, Hansford CF, Blondeau C, Bouveret le Cam NN. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. Vaccine 1999; 17: 110–13.

70.Proell S, Maiwald H, Nothdurft HD, et al. Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. J Travel Med 2002; 9: 122–26.

71.Loebermann M, Kollaritsch H, Ziegler T, et al. A randomized, openlabel study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. ClinTher 2004; 26: 1084–91.

72.Jong EC, Kaplan KM, Eves KA, Taddeo CA, Lakkis HD, Kuter BJ. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. J Travel Med 2002; 9: 66–70.

73.Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1: 1049–52. 74.Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a

Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990; 8: 81–84.

75.Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of entericcoated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336: 891–94.

76.Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338: 1055–59.

77.Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982; 145: 292–95.

78.Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17 (suppl 2): S22– 27.

79.Faucher JF, Binder R, Missinou MA, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147–54.

80.Begier EM, Burwen DR, Haber P, Ball R. Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis 2004; 38: 771–79.

81.Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263–69.

82.Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349: 1390–91.

83.John A Crump and Eric D Mintz-2009: Global trends in typhoid and paratyphoid fever. Clinical infectious diseases. 50:241-6



ISSN : 2581-7175 ©IJSRED: All Rights are Reserved Page 694 85.Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid

vaccines: a logical progression. Clin Infect Dis 2007;45: S20–3.





Download now (13 pages)